<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25910" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Physiology, Nociceptive Pathways</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kendroud</surname>
            <given-names>Sarah</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fitzgerald</surname>
            <given-names>Lauren A.</given-names>
          </name>
          <aff>Texas A&#x00026;M University - EnMed - Houston Methodist Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Murray</surname>
            <given-names>Ian V.</given-names>
          </name>
          <aff>Texas A&#x00026;M University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hanna</surname>
            <given-names>Andrew</given-names>
          </name>
          <aff>UCLA</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sarah Kendroud declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Lauren Fitzgerald declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ian Murray declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Andrew Hanna declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>9</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25910.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Nociception refers to the central nervous system (CNS) and peripheral nervous system (PNS) processing of noxious stimuli, such as tissue injury and temperature extremes, which activate nociceptors and their pathways. Pain is the subjective experience one feels as a result of the activation of these pathways. However, this perception depends on the action potential frequency, the time interval between each action potential, and input from higher-order brain centers. Pain is often used as a signal by the body to indicate that something is awry, but it may also arise from nerve misfiring or damage.<xref ref-type="bibr" rid="article-25910.r1">[1]</xref><xref ref-type="bibr" rid="article-25910.r2">[2]</xref><xref ref-type="bibr" rid="article-25910.r3">[3]</xref><xref ref-type="bibr" rid="article-25910.r4">[4]</xref></p>
      </sec>
      <sec id="article-25910.s2" sec-type="Cellular Level&#x0000d;&#x0000a;">
        <title>Cellular Level
</title>
        <p>The receptors responsible for relaying nociceptive information are termed nociceptors; they can be found on the skin, joints, viscera, and muscles. A wide variety of chemical substances activate these receptors, including globulin and protein kinases, arachidonic acid, histamine, nerve growth factor, substance P, calcitonin gene-related peptide (CGRP), potassium, serotonin, acetylcholine, low-pH solutions, adenosine triphosphate (ATP), and lactic acid. Receptors are also activated by temperature extremes, high pressures, and tissue damage causing inflammation.<xref ref-type="bibr" rid="article-25910.r5">[5]</xref><xref ref-type="bibr" rid="article-25910.r6">[6]</xref><xref ref-type="bibr" rid="article-25910.r7">[7]</xref></p>
        <p>Nociceptors can be further subdivided based on the type of information they are relaying. For instance, skin nociceptors can be divided into high-threshold mechanoreceptors (intense mechanical stimulation), thermal receptors (thermal and mechanical stimulation), chemical receptors, and polymodal receptors (high-intensity mechanical, thermal, and chemical stimulation). Joint nociceptors are classified as high-threshold mechanoreceptors, polymodal receptors, and silent receptors. Silent receptors are dormant in normal joints and&#x000a0;are unresponsive to stimuli such as heat or pressure. They become responsive only after tissue damage causes the release of inflammatory molecules in conditions such as arthritis. It is believed that patients with arthritis often complain of joint pain at rest due to these receptors suddenly becoming active and causing spontaneous neuronal firing. Additionally, these silent nociceptors may become mechanosensitive following inflammatory induction and can contribute to pain with movement in patients with arthritis. Joint nociceptors are classified as high-threshold mechanoreceptors, polymodal receptors, and silent receptors. Silent receptors are unresponsive to the initial stimuli of heat or pressure, but they become responsive only after tissue damage causes the release of inflammatory molecules. Visceral receptors are classified as mechanoreceptors, thermal, chemical, and silent receptors.<xref ref-type="bibr" rid="article-25910.r8">[8]</xref><xref ref-type="bibr" rid="article-25910.r9">[9]</xref></p>
        <p>Pain perception begins with free nerve endings, which are branches of the primary neuron that are unsheathed at the nerve tips but otherwise surrounded by Schwann cells. The multitude of different receptors conveys information that converges onto neuronal cell bodies in the dorsal root ganglion (stimulus from the body) and the trigeminal ganglia (stimulus from the face). There are&#x000a0;2 major nociceptive nerve fibers: A-delta fibers and C-fibers. A-delta fibers are lightly myelinated and have small receptive fields, which allow them to alert the body to the presence of pain. Due to the higher degree of myelination compared to C-fibers, these fibers are responsible for the initial perception of pain. Conversely, C-fibers are unmyelinated and have large receptive fields, which allow them to relay pain intensity.<xref ref-type="bibr" rid="article-25910.r10">[10]</xref><xref ref-type="bibr" rid="article-25910.r11">[11]</xref><xref ref-type="bibr" rid="article-25910.r12">[12]</xref></p>
      </sec>
      <sec id="article-25910.s3" sec-type="Mechanism">
        <title>Mechanism</title>
        <p>Nociceptive stimuli activate transient receptor potential (TRP) channels on nerve endings, which cause first-order neurons to depolarize and fire action potentials. Action potential frequency determines stimulus intensity. A-delta fibers release glutamate onto second-order neurons, while C-fibers release neuropeptide neurotransmitters. First-order neurons are found in the dorsal root ganglion (stimulus from the body) and trigeminal ganglia (stimulus from the face). A-delta and C-fibers are associated with first-order neurons found in the nucleus posterior marginalis of Rexed layer I and substantia gelatinosa of Rexed layer II. From Rexed layer I and II, these neurons form projections that comprise the&#x000a0;3 major ascending pain pathways: the neospinothalamic, paleospinothalamic, and archispinothalamic tracts.</p>
        <p>The neospinothalamic tract begins with nociceptive neurons located in Rexed layer I. Second-order neurons decussate at the anterior white commissure and ascend via the lateral spinothalamic tract. Third-order neurons are in the ventral posterolateral nucleus (VPL) and the ventral posterior inferior nucleus (VPI). From the thalamus, nociceptive information projects to the primary somatosensory cortex for further processing and pain perception. Nociceptive information from the face and intraoral structures is transmitted via first-order neurons in the trigeminal ganglia, which project to the pons and spinal trigeminal nucleus in the medulla before synapsing with neurons in the ventral posteromedial nucleus (VPM), parafascicular nucleus (PF), and the centromedian nucleus (CM). Similar to nociceptive information from the body, the information further projects to the primary somatosensory cortex.</p>
        <p>The paleospinothalamic tract is the second of the&#x000a0;3 ascending pain pathways. First-order neurons of this pathway are found in Rexed layer II, which project diffusely to Rexed layers IV through VIII. From the spinal cord, these projections travel anteriorly and project bilaterally onto the mesencephalic reticular formation, periaqueductal gray, tectum, PF, and CM. The PF and CM neurons send projections to the somatosensory cortex, brainstem nuclei, and limbic areas (cingulate gyrus, insulate cortex). The interplay mediates emotional and visceral responses to pain between the limbic structures, hypothalamus, and brainstem nuclei.</p>
        <p>The archispinothalamic tract also mediates visceral and emotional reactions to pain. First-order neurons are found in Rexed layer II, which project to neurons in Rexed layers IV and VII. Diffuse projections from the latter&#x000a0;2 layers are sent to the midbrain reticular formation and the periaqueductal gray. Neurons in the midbrain reticular formation and periaqueductal gray then send projections to the hypothalamus, limbic system nuclei, PF, and CM nucleus.</p>
        <p>The body is also capable of suppressing pain signals from these ascending pathways. Opioid receptors are found at various sites at the level of the spinal cord and in structures such as the periaqueductal gray, nucleus raphe magnus, dorsal raphe, rostral ventral medulla, caudate nucleus, septal nucleus, hypothalamus, habenula, and hippocampus. At the level of the spinal cord, these G-protein&#x02013;coupled receptors are found on the presynaptic ends of nociceptive neurons of Rexed layers IV through VII. Beta-endorphins, enkephalins, and dynorphins serve as ligands that activate these receptors and cause cell hyperpolarization via activating potassium channels and blocking calcium influx&#x02014;the subsequent inhibition of substance P results in blocked pain transmission. The descending pain suppression pathway is a circuit composed of the periaqueductal gray, locus coeruleus, nucleus raphe magnus, and nucleus reticularis gigantocellularis. The periaqueductal gray and its associated structures modulate the body's response to stress, especially pain, via opioid receptors. It suppresses information carried via C-fibers, not A-delta fibers, by inhibiting local GABAergic interneurons.</p>
      </sec>
      <sec id="article-25910.s4" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Complex regional pain syndrome (CRPS) is a neurological condition in which one experiences severe, chronic pain alongside sensory, autonomic, motor, and trophic impairment, primarily affecting the limbs. Type-I CRPS is not limited to a single nerve; therefore, pain is felt diffusely with an emphasis on the distal aspect of the extremity. It is characterized by pain, allodynia, abnormal sudomotor activity, and blood flow. In contrast, type-II CRPS is limited to a few nerves and their branches. It is associated with burning pain, allodynia, and hyperpathia. The pain is not correlated with any evidence of nerve damage, but minor injuries, trauma, and surgery can induce it. While the exact pathophysiology of CRPS is unclear, it is currently hypothesized that an exaggerated response to inflammation triggers it. The release of proinflammatory factors after tissue injury leads to the cardinal features of inflammation (redness, increased heat, swelling, pain, and loss of function), which also correspond to the features of CRPS. Persistent inflammation is also accompanied by a decreased threshold for pain and an enhanced responsiveness to pain. Neuropeptides, such as substance P, bradykinin, and glutamate, mediate the increased activity of secondary nociceptive neurons in the pain circuitry, leading to enhanced pain perception. In the chronic phase of CRPS, increased adrenergic receptors on nociceptive neurons demonstrate that the increased sympathetic drive mediates the continued perception of pain. Currently, physical and occupational therapy is considered the first-line therapy for managing CRPS.</p>
      </sec>
      <sec id="article-25910.s5">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25910&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25910">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25910/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25910">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25910.s6">
        <title>References</title>
        <ref id="article-25910.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ram&#x000ed;rez-Morales</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;ndez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rudomin</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Descending inhibition selectively counteracts the capsaicin-induced facilitation of dorsal horn neurons activated by joint nociceptive afferents.</article-title>
            <source>Exp Brain Res</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>237</volume>
            <issue>7</issue>
            <fpage>1629</fpage>
            <page-range>1629-1641</page-range>
            <pub-id pub-id-type="pmid">30949729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25910.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goudman</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brouns</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>De Groote</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>De Jaeger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Huysmans</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Forget</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Moens</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Association Between Spinal Cord Stimulation and Top-Down Nociceptive Inhibition in People With Failed Back Surgery Syndrome: A Cohort Study.</article-title>
            <source>Phys Ther</source>
            <year>2019</year>
            <month>Jul</month>
            <day>01</day>
            <volume>99</volume>
            <issue>7</issue>
            <fpage>915</fpage>
            <page-range>915-923</page-range>
            <pub-id pub-id-type="pmid">30916768</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25910.r3">
          <label>3</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Shah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Padalia</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <chapter-title>Intrathecal Delivery System</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>12</month>
            <day>9</day>
            <pub-id pub-id-type="pmid">30855825</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25910.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Puopolo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The hypothalamic-spinal dopaminergic system: a target for pain modulation.</article-title>
            <source>Neural Regen Res</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>14</volume>
            <issue>6</issue>
            <fpage>925</fpage>
            <page-range>925-930</page-range>
            <pub-id pub-id-type="pmid">30761995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25910.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pereira</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Goudet</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Emerging Trends in Pain Modulation by Metabotropic Glutamate Receptors.</article-title>
            <source>Front Mol Neurosci</source>
            <year>2018</year>
            <volume>11</volume>
            <fpage>464</fpage>
            <pub-id pub-id-type="pmid">30662395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25910.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bahari</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Meftahi</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>Spinal &#x003b1;<sub>2</sub> -adrenoceptors and neuropathic pain modulation; therapeutic target.</article-title>
            <source>Br J Pharmacol</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>176</volume>
            <issue>14</issue>
            <fpage>2366</fpage>
            <page-range>2366-2381</page-range>
            <pub-id pub-id-type="pmid">30657594</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25910.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Szabadi</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Functional Organization of the Sympathetic Pathways Controlling the Pupil: Light-Inhibited and Light-Stimulated Pathways.</article-title>
            <source>Front Neurol</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>1069</fpage>
            <pub-id pub-id-type="pmid">30619035</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25910.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McDougall</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Arthritis and pain. Neurogenic origin of joint pain.</article-title>
            <source>Arthritis Res Ther</source>
            <year>2006</year>
            <volume>8</volume>
            <issue>6</issue>
            <fpage>220</fpage>
            <pub-id pub-id-type="pmid">17118212</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25910.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gold</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Gebhart</surname>
                <given-names>GF</given-names>
              </name>
            </person-group>
            <article-title>Nociceptor sensitization in pain pathogenesis.</article-title>
            <source>Nat Med</source>
            <year>2010</year>
            <month>Nov</month>
            <volume>16</volume>
            <issue>11</issue>
            <fpage>1248</fpage>
            <page-range>1248-57</page-range>
            <pub-id pub-id-type="pmid">20948530</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25910.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zieglg&#x000e4;nsberger</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Substance P and pain chronicity.</article-title>
            <source>Cell Tissue Res</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>375</volume>
            <issue>1</issue>
            <fpage>227</fpage>
            <page-range>227-241</page-range>
            <pub-id pub-id-type="pmid">30284083</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25910.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koivisto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jalava</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bratty</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pertovaara</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>TRPA1 Antagonists for Pain Relief.</article-title>
            <source>Pharmaceuticals (Basel)</source>
            <year>2018</year>
            <month>Nov</month>
            <day>01</day>
            <volume>11</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">30388732</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25910.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>P&#x000e9;rez de Vega</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Ferrer-Montiel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-Mu&#x000f1;iz</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Recent progress in non-opioid analgesic peptides.</article-title>
            <source>Arch Biochem Biophys</source>
            <year>2018</year>
            <month>Dec</month>
            <day>15</day>
            <volume>660</volume>
            <fpage>36</fpage>
            <page-range>36-52</page-range>
            <pub-id pub-id-type="pmid">30342013</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
